PHILADELPHIA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The Aspire Academy Global Summit 2025 brought together some of the most influential minds in football for two days of dialogue and discovery at Subaru Park, home of the Philadelphia Union in Philadelphia, USA.

... Read more »

Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory mantle cell lymphoma (MCL) BeOne to participate in Project Orbis program, supporting efforts to rapidly advance global access (BUSINESS WIRE) -- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Additionally, the FDA has accepted BeOne’s request for participation in Project Orbis, an initiative that provides a framework for concurrent submission and review of oncology products among participating global health authorities. “Breakthrough Therapy Designation is reserved for medicines with the potential to tran ... Read more »

LONDON - Friday, 10. October 2025 AETOSWire Print 

(BUSINESS WIRE)--12BET, shaping the igaming landscape since 2007, has been shortlisted for “Best Customer Service” at the EGR Operator Awards 2025. This recognition highlights 12BET’s commitment to building trust, transparent interactions, and placing customer satisfaction at the heart of its operations. Being named a finalist shows how 12BET’s service philosophy sets new standards in responsiveness, empathy, and professionalism across its global player community.

In 2025, 12BET strengthened its customer-first approach with honest communication and transparent service. A structured Trustpilot review program invited genuine feedback from long-standing users, building public trust while informing service improvements. This reflects 12BET’s belief that customer feedback should not only resolve issues but also inspire continuous learning ... Read more »

PARIS - Friday, 10. October 2025 AETOSWire 

(BUSINESS WIRE)--Vantiva (Euronext Paris: VANTI), a global technology leader in connectivity, today announced that the Science Based Targets initiative (SBTi) has approved the company's near- and long-term science-based targets, confirming that Vantiva's targets align with the latest climate science and the 1.5°C ambition of the Paris Agreement.

The SBTi's approval of Vantiva's science-based targets demonstrates the company's commitment to measurable decarbonization. Vantiva's targets with a 2021 base year include:

By 2030: Reduce absolute Scope 1 and 2 GHG emissions by 80.0%, absolute Scope 3 GHG emissions from the use of sold products by 60.0%, and overall absolute Scope 3 GHG emissions by 55.0%.
By 2040 (Net-zero target): Reduce absolute Scope 1 and 2 GHG emissions by 90.0% and absolute Scope 3 GHG emissions by 90.0%.
This accelerates Vantiva's net-zero goal ten ye ... Read more »

Hainan, China 
The World Free Zones Organization’s 11th annual World Congress continued its agenda today with a focus on the role of digitization and sustainability in the future of free zones and the mechanisms for enhancing their position as strategic trade gateways.

The day’s sessions featured a series of sessions addressing critical themes such as the digitization of trade corridors, the impact of the OECD Global Minimum Tax, and the role of free zones as regional trade gateways.

Sustainability took centre stage with sessions focusing on the transition to net-zero through renewable energy, circular economy models, and green financing frameworks. Speakers underscored that decarbonization is not only a climate imperative but also a competitive advantage for the next generation of free zones.

The Congress also witnessed the inauguration of the Global Free Zones Research Institute, a pioneering international think tank dedicated to adva ... Read more »

For Trade and Medical Media Only

 

 

• Enrolment completed in Phase III ReSPECT study in prophylaxis of fungal infections in adult patients undergoing allogeneic blood and marrow transplant
• Topline results from ReSPECT study expected by mid-2026

 

 

(BUSINESS WIRE)--Mundipharma today announced completion of patient enrolment for the ongoing, global Phase III ReSPECT trial evaluating REZZAYO® (rezafungin).

The ReSPECT trial is a global, randomised, double-blind, controlled, pivotal Phase 3 trial of rezafungin versus the standard antimicrobial regimen to prevent invasive fungal disease due to Candida, Aspergillus and Pneumocystis in subjects undergoing allogeneic blood and marrow transplantation.

“Completing patient enrolment for the Phase III ReSPECT study marks a key milestone in addressing the unmet need for antifungal prevention in immunosuppressed patients,” s ... Read more »